Luo Zhang

1 month ago | onlinelibrary.wiley.com | Feng Lan |Beijing Laboratory |Cezmi A. Akdis |Luo Zhang

Biologics are increasingly becoming the treatment of choice for allergic diseases that are unresponsive to standard treatments, such as chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, allergic rhinitis (AR), atopic dermatitis (AD), and prurigo nodularis [1-3]. Key biologics targeting type 2 (T2) inflammation include dupilumab and stapokibart, both of which block interleukin 4 receptor alpha (IL-4Rα) at distinct binding epitopes.

Apr 11, 2024 | tandfonline.com | Yuan Zhang |Luo Zhang

KEYWORDS: Adherenceallergic rhinitisallergen-specific immunotherapybiologicspharmacotherapyreal-world evidence 1. IntroductionAllergic rhinitis (AR) is a chronic inflammatory disease caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens in the nasal mucosa, resulting in nasal itching, rhinorrhea, sneezing, and obstruction. As one of the most common chronic conditions globally, AR affects up to 50% of the population worldwide [Citation1].